plerixafor has been researched along with Thyroid Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dizdar, L; Forster, CM; Knoefel, WT; Krieg, A; Raba, K; Schott, M; Verde, PE; Werner, TA | 1 |
| Ahn, SH; Cha, W; Jung, YH; Kim, BH; Kim, KH; Lee, DY; Sung, MW | 1 |
2 other study(ies) available for plerixafor and Thyroid Neoplasms
| Article | Year |
|---|---|
CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antigens, CD; Benzylamines; Cadherins; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Chemokine CXCL12; Child; Cyclams; Epithelial-Mesenchymal Transition; Female; Fibroblast Growth Factor 9; Gene Expression; GPI-Linked Proteins; Heterocyclic Compounds; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Prognosis; Receptors, CXCR; Receptors, CXCR4; Recombinant Proteins; Retrospective Studies; Snail Family Transcription Factors; Survival Rate; Thyroid Neoplasms; Tissue Array Analysis; Tumor Burden; Vimentin; Young Adult | 2017 |
Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cells.
Topics: Animals; Benzylamines; Carcinogenesis; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Cyclams; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Immunohistochemistry; Mice; Mice, Nude; Receptors, CXCR4; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |